Marking its 40th anniversary, Korea GSK said it will continue to strengthen patient-centered values despite the changing healthcare environment.
Kuna Riediger, CEO of Korea GSK, said at an employee event on the 8th marking the 40th anniversary, "The past 40 years are achievements built through the dedication and collaboration of employees and partners," and added, "Going forward, we will keep patients at the center of all our activities with a focus on innovation and collaboration and contribute to the development of Korea's healthcare."
GSK plc (GSK) is a global pharmaceutical company headquartered in London. Established in 1986, the Korean subsidiary Korea GSK has continued its business in the domestic market with a focus on vaccines and prescription medicines. It now spans prevention to the treatment of chronic and severe diseases based on its vaccines, specialty medicines, and general medicine portfolios.
Korea is one of GSK's global research and development (R&D) focus countries and actively participates in clinical research across all phases, from early research to late-stage development. GSK is continuously consolidation the bio industry, including domestic medical and research professionals, with global research and development projects. Korea GSK plans to contribute to patients and local communities through social contribution activities linked to each business unit's vision.